Related Experiment Video
Updated: Nov 4, 2025
05:05
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
571
Repository Corticotropin Injection as an Alternative Treatment for Refractory Ocular Mucous Membrane Pemphigoid.
Yael Sharon1,2,3, Stephen D Anesi4,5, Christine E Martinez6,7
1Department of Ophthalmology, Rabin Medical Center, Petah-Tikva, Israel.
Cornea
|May 29, 2021
Summary
Repository corticotropin injection (RCI) may offer a safe and effective treatment option for severe ocular mucous membrane pemphigoid (MMP). This study found RCI helped control disease activity in refractory MMP cases.
Area of Science:
- Ophthalmology
- Immunodermatology
- Rheumatology
Background:
- Ocular mucous membrane pemphigoid (MMP) is a severe, chronic autoimmune blistering disease.
- Refractory cases often present significant challenges in management and require alternative therapeutic strategies.
Purpose of the Study:
- To evaluate the clinical course and outcomes of repository corticotropin injection (RCI) in patients with refractory ocular MMP.
- To assess the safety and efficacy of RCI as a treatment for severe ocular MMP.
Main Methods:
- Retrospective review of 15 patients with biopsy-proven ocular MMP treated with RCI across three tertiary centers.
- Data collected between January 2013 and January 2021, focusing on disease activity, scarring, and complications.
- Primary outcomes included changes in conjunctival inflammation, Foster scarring stage, and adverse events.
Main Results:
- All 15 patients had active, refractory ocular MMP, with 80% at Foster stage 3.
- Nine patients (60%) had failed at least two prior immunomodulatory agents.
- RCI treatment, averaging 21 months, controlled disease activity in 9 patients, with no serious adverse events reported.
Conclusions:
- Repository corticotropin injection (RCI) demonstrates potential as an alternative or adjunctive therapy for severe, refractory ocular MMP.
- RCI appears to be a safe and well-tolerated treatment option for this challenging condition.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
782
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
782
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
265
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
265